Volume | 10,061 |
|
|||||
News | - | ||||||
Day High | 1.7346 | Low High |
|||||
Day Low | 1.70 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sonnet BioTherapeutics Holdings Inc | SONN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.72 | 1.70 | 1.7346 | 1.70 | 1.67 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
116 | 10,061 | $ 1.71 | $ 17,208 | - | 1.08 - 26.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:41:45 | 43 | $ 1.65 | USD |
Sonnet BioTherapeutics Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.22M | 3.07M | - | 148k | -18.83M | -6.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sonnet BioTherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SONN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.95 | 2.10 | 1.65 | 1.86 | 26,016 | -0.25 | -12.82% |
1 Month | 2.20 | 2.2664 | 1.65 | 1.98 | 35,389 | -0.50 | -22.73% |
3 Months | 1.36 | 2.3399 | 1.31 | 1.97 | 109,386 | 0.34 | 25.00% |
6 Months | 2.38 | 2.6099 | 1.08 | 1.75 | 89,903 | -0.68 | -28.57% |
1 Year | 7.2226 | 26.40 | 1.08 | 9.74 | 1,436,386 | -5.52 | -76.46% |
3 Years | 640.64 | 840.84 | 1.08 | 150.40 | 2,927,745 | -638.94 | -99.73% |
5 Years | 1,915.76 | 4,989.60 | 1.08 | 329.85 | 2,628,814 | -1,914.06 | -99.91% |
Sonnet BioTherapeutics Description
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |